multi-center study and compared to radical nephrectomy (RN) performed in the same centers for tumors of comparable diameter and VTT. Demographics, perioperative complications, functional, and oncologic outcomes were compared between the two groups. Mean, median, standard deviation, and interquartile range (IQR) were used to report continuous variables, as appropriate. Survival analysis were used to assess recurrence free survival (RFS), cancer specific survival (CSS) and overall survival (OS). Univariable (UVA) and multivariable (MVA) analyses were used to evaluate variables predicting complications, OS, CSS and RFS, and end-stage renal disease (ESRD, eGFR<30).
INTRODUCTION AND OBJECTIVES: Nearly half of all patients undergoing partial nephrectomy (PNx) for cT1 tumors will have adverse final pathologic features such as high Fuhrman grade or pT3a disease. While renal mass biopsy can aid in the identification of high grade disease, tools to predict tumor upstaging are limited. Given that preoperative risk factors associated with pT3a upstaging are not well defined we sought to identify predictors of pT3a disease in patients undergoing PNx for cT1 disease.
METHODS: A retrospective chart review was completed to identify patients with cT1 renal masses who underwent open or minimally-invasive PNx between 2000-2014. All patients with imaging sufficient for R.E.N.A.L Nephrometry scoring were included. The primary outcome was upstaging to pT3a disease at final pathology. All patients with benign final pathology were excluded. Univariate and multivariate logistic regression analyses were performed to identify characteristics independently associated with pT3a upstaging. All variables with a pvalue of 0.1 on univariate analysis were included in the multivariate analysis.
RESULTS: A total of 508 patients were identified, of which 449 (88%) had final pT1 and 59 (12%) had final pT3a disease. The etiology of pT3a upstaging was perinephric adipose extension in 69% (41/59), renal sinus fat invasion in 28% (14/59), and microscopic segmental or renal vein invasion in 7% (4/59). Patient age (p¼0.012), ASA classification (p¼0.005), preoperative radiologic tumor size (p¼0.079), and high R.E.N.A.L Nephrometry Score complexity (p¼0.017) were all associated with pT3a upstaging on univariate analysis. Multivariate analysis demonstrated a significant and independent association of patient age (p¼0.025), preoperative radiologic tumor size (p¼0.014), and high R.E.N.A.L Nephrometry Score complexity (p¼0.019) with pT3a upstaging.
CONCLUSIONS: In patients who undergo PNx for cT1 disease, patient age, preoperative radiologic tumor size, and high R.E.N.A.L Nephrometry Score complexity represent readily measurable preoperative characteristics that are associated with increased risk of pT3a upstaging. The presence of these features may be utilized for operative planning to ensure adequate resection and negative margins in patients at increased risk for pathologic upstaging. Because studies are limited due to the rarity of this variant, we reviewed our experience with ccRCC and report on long term oncologic outcomes of cystic ccRCC. METHODS: We identified 3,865 patients treated with radical or partial nephrectomy for unilateral, sporadic ccRCC between 1970 and 2010. One urologic pathologist re-reviewed all pathologic slides, blinded to patient outcome. Cancer-specific survival (CSS) was estimated using the Kaplan-Meier method and compared between those with and without cystic ccRCC using log-rank tests.
Source of Funding: None
RESULTS: Overall, 158 of 3,865 (4%) patients had cystic ccRCC. Compared to patients with non-cystic ccRCC, patients with cystic ccRCC were younger (median 58 vs. 63 years, p<0.001), were more likely to have radiographic evidence of cystic structures (60% vs. 17%, p<0.001), were less likely to have distant metastases at surgery (0% vs. 14%, p<0.001), and had smaller tumors (median 3.0 vs. 6.0cm, p<0.001) that were less likely to contain coagulative tumor necrosis (1% vs. 29%, p<0.001) or sarcomatoid differentiation (0% vs. 5%, p¼0.006). With a median follow-up for survivors of 10.5 years (IQR 7.3-14.9), 63 patients with cystic ccRCC died at a median of 7.7 years after surgery (IQR 3.8-11.9). However, only one patient died from RCC after developing metastases 22 years after the initial surgery. CSS rates at 25 years following surgery were significantly better for cystic ccRCC compared to non-cystic ccRCC (88% vs. 52%, p<0.001) (Figure 1) , even among the subset of pT1, pNX/0, M0 patients (100% vs. 83%, p¼0.001).
CONCLUSIONS: In a large cohort of ccRCC patients with pathologic re-review and long-term follow-up, our results suggest that cystic ccRCC is both uncommon and associated with a very favorable prognosis.
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